Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR35 | Q9HC97 | 5/20 | 0.67 |
| ▸ | CCR2 | P41597 | 7/20 | 0.59 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.59 |
| ▸ | F10 | P00742 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | CLK1 | P49759 | 1/20 | 0.44 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.44 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5023537 | 0.87 | GPR35 (0.67) | GPR35CCR2ABCB11ALDH1A1CYP1A2 | |
| SCHEMBL9613337 | 0.84 | GPR35 (0.62) | GPR35CCR2ALDH1A1KDM4EMEN1 | |
| SCHEMBL7378692 | 0.83 | ALDH1A1 (0.65) | GPR35CCR2ABCB11F10ALDH1A1 | |
| SCHEMBL38664558 | 0.83 | MCL1 (0.65) | GPR35CCR2ABCB11ALDH1A1KDM4E | |
| SCHEMBL708583 | 0.83 | MCL1 (0.65) | GPR35CCR2ABCB11ALDH1A1KDM4E | |
| SCHEMBL700700 | 0.83 | CCR2 (0.65) | GPR35CCR2ABCB11 | |
| SCHEMBL18733287 | 0.82 | ABCB11 (0.51) | GPR35CCR2ABCB11F10ALDH1A1 | |
| SCHEMBL30547765 | 0.81 | CCR2 (0.53) | GPR35CCR2ABCB11F10ALDH1A1 | |
| SCHEMBL2002926 | 0.80 | CCR2 (0.74) | GPR35CCR2ABCB11F10 | |
| SCHEMBL2767702 | 0.80 | CCR2 (0.59) | GPR35CCR2ABCB11F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2968272-B1 | USE OF INDOLE COMPOUNDS FOR FAT REDUCTION AND SKIN AND SOFT TISSUE TIGHTENING | ALEVERE MEDICAL CORP (US) | 2021-06-16 | — | — | EP | disclosed |
| US-10653670-B2 | Use of indole compounds for fat reduction and skin and soft tissue tightening | ALEVERE MEDICAL CORPORATION (US) | 2020-05-19 | — | — | US | disclosed |
| US-20190290613-A1 | USE OF INDOLE COMPOUNDS FOR FAT REDUCTION AND SKIN AND SOFT TISSUE TIGHTENING | ALEVERE MEDICAL CORPORATION | 2019-09-26 | — | — | US | disclosed |
| US-10258605-B2 | Use of indole compounds for fat reduction and skin and soft tissue tightening | ALEVERE MEDICAL CORPORATION (US) | 2019-04-16 | — | — | US | disclosed |
| US-20180193309-A1 | USE OF INDOLE COMPOUNDS FOR FAT REDUCTION AND SKIN AND SOFT TISSUE TIGHTENING | ALEVERE MEDICAL CORPORATION | 2018-07-12 | — | — | US | disclosed |
| US-20160030389-A1 | USE OF INDOLE COMPOUNDS FOR FAT REDUCTION AND SKIN AND SOFT TISSUE TIGHTENING | ALEVERE MEDICAL CORP (US) | 2016-02-04 | — | — | US | disclosed |
| EP-1968967-B1 | 1,1-DIOXO-THIOMORPHOLINYL INDOLYL METHANONE DERIVATIVES FOR USE AS H3 MODULATORS | HOFFMANN LA ROCHE (CH) | 2011-04-27 | — | — | EP | disclosed |
| EP-1960383-B1 | 5-SUBSTITUTED INDOLE-2-CARBOXAMIDE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2010-04-28 | — | — | EP | disclosed |
| US-7538101-B2 | 1,1-dioxo-thiomorpholinyl indolyl methanone derivatives | HOFFMANN-LA ROCHE INC. (US) | 2009-05-26 | — | — | US | disclosed |
| US-20090118349-A1 | BIS-ALKYLATING AGENTS AND THEIR USE IN CANCER THERAPY | ONCO-PHARMAKON INCORPORATED (US) | 2009-05-07 | — | — | US | disclosed |
| US-7388095-B2 | 5-substituted indole-2-carboxamide derivatives | HOFFMANN-LA ROCHE INC. (US) | 2008-06-17 | — | — | US | disclosed |
| EP-1761519-B1 | INDOLE DERIVATIVES AS HISTAMINE RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2008-05-07 | — | — | EP | disclosed |
| US-7361682-B2 | Indole derivatives as H3 inverse agonists | HOFFMANN-LA ROCHE INC. (US) | 2008-04-22 | — | — | US | disclosed |
| WO-2007063000-A1 | 5-SUBSTITUTED INDOLE-2-CARBOXAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-06-07 | — | — | WO | disclosed |
| WO-2007062997-A1 | 1,1-DIOXO-THIOMORPHOLINYL INDOLYL METHANONE DERIVATIVES FOR USE AS H3 MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-06-07 | — | — | WO | disclosed |
| US-20070123526-A1 | 1,1-Dioxo-thiomorpholinyl indolyl methanone derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2007-05-31 | — | — | US | disclosed |
| US-20070123525-A1 | 5-Substituted indole-2-carboxamide derivatives | HOFFMANN-LA ROCHE INC. | 2007-05-31 | — | — | US | disclosed |
| EP-1761519-A1 | INDOLE DERIVATIVES AS HISTAMINE RECEPTOR ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2007-03-14 | — | — | EP | disclosed |
| WO-2005123716-A1 | INDOLE DERIVATIVES AS HISTAMINE RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-12-29 | — | — | WO | disclosed |
| US-20050282864-A1 | Indole derivatives as H3 inverse agonists | HOFFMANN-LA ROCHE INC. | 2005-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118349-A1 | BIS-ALKYLATING AGENTS AND THEIR USE IN CANCER THERAPY | UNG, MPG, DIMT1 | GPR35 757/4885CCR2 3366/4885ABCB11 1684/4885 |
| US-20180193309-A1 | USE OF INDOLE COMPOUNDS FOR FAT REDUCTION AND SKIN AND SOFT TISSUE TIGHTENING | IDO1, FABP4, IDO2 | GPR35 1258/4885CCR2 3550/4885ABCB11 4081/4885 |
| US-20050282864-A1 | Indole derivatives as H3 inverse agonists | HRH3, HRH4, ADRB1 | GPR35 72/4885CCR2 507/4885ABCB11 1288/4885 |
| US-20190290613-A1 | USE OF INDOLE COMPOUNDS FOR FAT REDUCTION AND SKIN AND SOFT TISSUE TIGHTENING | IDO1, FABP4, IDO2 | GPR35 1258/4885CCR2 3550/4885ABCB11 4081/4885 |
| US-20070123525-A1 | 5-Substituted indole-2-carboxamide derivatives | HRH4, HRH3, HCAR2 | GPR35 26/4885CCR2 488/4885ABCB11 1009/4885 |
| US-20160030389-A1 | USE OF INDOLE COMPOUNDS FOR FAT REDUCTION AND SKIN AND SOFT TISSUE TIGHTENING | IDO1, FABP4, IDO2 | GPR35 1258/4885CCR2 3550/4885ABCB11 4081/4885 |
| US-10653670-B2 | Use of indole compounds for fat reduction and skin and soft tissue tightening | IDO1, FABP4, IDO2 | GPR35 1258/4885CCR2 3550/4885ABCB11 4081/4885 |
| US-10258605-B2 | Use of indole compounds for fat reduction and skin and soft tissue tightening | IDO1, FABP4, IDO2 | GPR35 1258/4885CCR2 3550/4885ABCB11 4081/4885 |
| US-20070123526-A1 | 1,1-Dioxo-thiomorpholinyl indolyl methanone derivatives | MTNR1A, HTR1A, HRH4 | GPR35 134/4885CCR2 524/4885ABCB11 742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.